- Caribou Biosciences Inc (NASDAQ:CRBU) announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
- Following a single dose at the initial dose level of 40 million CAR-T cells, a 100% complete response (CR) rate (6 of 6 patients) was observed as the best response.
- Related: Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study.
- At 6 months following the single dose of CB-010, 40% of patients remained in CR (2 of 5 patients) as of the May 13 data cutoff date.
- One patient suffered grade 3 immune effector cell-associated neurotoxicity syndrome that resolved in 39 hours. Still, none of the patients experienced graft-versus-host disease or grade 2 or greater cytokine release syndrome (CRS). Two patients had grade 1 CRS.
- Caribou has begun enrolling patients at the second dose level, 80 million CAR-T cells. Doubling the dose could drive longer-lasting responses.
- "Our conviction is intact that the recent dataset positions CRBU to potentially differentiate vs. competitors in a meaningful and favorable way as data matures and the company explores larger patient numbers and higher dose(s)," SVB Securities wrote.
- HC Wainwright says that CB-010's response rate and the complete response rate are more competitive than those seen with the FDA-approved CAR-T agents.
- It notes that Gilead Sciences Inc's (NASDAQ:GILD) Yescarta demonstrated a 74% ORR (54% CR) and 94% ORR (79% CR) in DLBCL and FL, respectively, and Novartis AG's (NYSE:NVS) Kymriah demonstrated a 53% ORR (39% CR) and 87% ORR (68% CR) in DLBCL and FL, respectively.
- Price Action: CRBU shares are down 25.70% at $5.16 during the market session on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks